-
JBCRG-02
Study of fluorouracil, epirubicin and cyclophosphamide followed by docetaxel as preoperative chemotherapy in primary breast cancer
- Status
-
Study Closed
- Objectives
-
To evaluate clinical, histologic effect and safety of primary systemic chemotherapy using FEC followed by docetaxel in primary breast cancer
- Subjects
-
- Endpoints
-
Primary endpoint: Safety, clinical and histologic effect, Secondary endpoints: Breast-conserving rate, disease-free survival
- Trial Period
-
August 2004 - January 2012 (Registration: 2 years, Follow-up study: 5 years)
- Lead Principal Investigator
-
Seigo Nakamura (Breast Center, St. Luke's International Hospital)
- Target Sample Size
-
ver1.0：31 patients／ver1.1：19 patients
- Regimen
-
FEC100 q3w x4->Doc100 q3wx4
- Source of Funding
-
ACRO: Advanced Clinical Research Organization
- Conference Presentation
-
- Articles and Publications
-
Comparison of different definitions of pathologic complete response in operable breast cancer; a pooled analysis of three prospective neoadjuvant studies of JBCRG
Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients With Primary Breast Cancer
- UMIN-ID
-
C000000020
- jRCT
-
- Memo
-
- COI Disclosure
-
